lansoprazole has been researched along with Hepatocellular Carcinoma in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kikuchi, H | 1 |
| Kato, H | 1 |
| Mizuno, M | 1 |
| Hossain, A | 1 |
| Ikawa, S | 1 |
| Miyazaki, J | 1 |
| Watanabe, M | 1 |
1 other study available for lansoprazole and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Differences in inducibility of CYP1A1-mRNA by benzimidazole compounds between human and mouse cells: evidences of a human-specific signal transduction pathway for CYP1A1 induction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Li | 1996 |